Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

Patient Voices Highlight the Realities of Living with Irritable Bowel Syndrome During IBS Awareness Month

Bausch Health's gastroenterology business, Salix Pharmaceuticals, recognizes the complexities of irritable bowel syndrome (IBS) and seeks to make a difference in how the condition is perceived, diagnosed and treated.

LAVAL, QC / ACCESS Newswire / April 2, 2025 / Bausch Health Companies Inc. (NYSE: BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), today announced the launch of IBS Symptoms Aren't Black and White: Living in the Gray, an authentic storytelling campaign that addresses the complexities of living with irritable bowel syndrome (IBS). Throughout April, which is IBS Awareness Month, Salix will be sharing patient stories on LinkedIn, highlighting the unique journeys of individuals living with IBS.

Irritable bowel syndrome is more than just a common condition that affects up to an estimated 10% of the global population - it is a complex condition with unpredictable symptoms that can impact every aspect of patients' lives, including one's physical, emotional, social and professional well-being.1,2 Navigating the road to proper care can be a long and complicated process; Salix seeks to bring greater understanding to help improve how IBS is perceived, diagnosed and treated.

"We recognize that every patient's experience is unique and has the potential to inspire others in the IBS community to seek the care they deserve," said Nicola Kayel, Senior Vice President, Marketing, Salix. "Our campaign, IBS Symptoms Aren't Black & White: Living in the Gray, underscores our ongoing commitment to supporting patients by amplifying their voices to raise visibility, build a community of empowered individuals and destigmatize the narrative that surrounds this condition."

Many people with IBS agree that their symptoms, such as diarrhea and hard to pass bowel movements, can be hard to talk about, and as a result, unresolved symptoms cause the burden of IBS to persist.2 Patient advocacy group, the International Foundation for Gastrointestinal Disorders (IFFGD), recognizes this obstacle and is partnering with Salix to generate conversation and share authentic stories. By normalizing open and honest discussions about IBS and reducing stigma, Salix and IFFGD hope to motivate patients to talk to their healthcare providers about the full range of their IBS symptoms, including less obvious experiences like abdominal pain, bloating and urgency.

President of IFFGD, Ceciel T. Rooker, stated, "At IFFGD, we are committed to broadening patient understanding of GI disorders like IBS. We are proud to support Salix in their effort to illuminate real patient stories to help raise visibility of the authentic patient experience and the multi-faceted nature of IBS symptoms. We believe it will encourage patients to speak up about their symptoms and ultimately receive appropriate care for their condition."

Click here to read about real patients' experiences on Salix Pharmaceuticals' LinkedIn.

##

About Bausch Health

Bausch Health Companies Inc. (NYSE: BHC)(TSX:BHC) is a global, diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb Corporation. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors. Our gastroenterology business, Salix Pharmaceuticals, is one of the largest specialty pharmaceutical businesses in the world and has licensed, developed and marketed innovative products for the treatment of gastrointestinal diseases for more than 30 years. For more information about Salix, visit www.Salix.com and connect with us on Twitter and LinkedIn. For more information about Bausch Health, visit www.bauschhealth.com and connect with us on LinkedIn.

References

  1. Mayo Clinic. (2023). Irritable Bowel Syndrome (IBS). Retrieved from https://www.mayoclinic.org/diseases-conditions/irritable-bowel-syndrome/symptoms-causes/syc-20360016

  2. International Foundation for Functional Gastrointestinal Disorders (IFFGD). (2024) IBS Facts and Statistics. AboutIBS.org. https://aboutibs.org/what-is-ibs/facts-about-ibs/.

©2025 Salix Pharmaceuticals or its affiliates.

Investor Contact:
Garen Sarafian
ir@bauschhealth.com
877-281-6642 (toll-free)

Media Contact:
Katie Savastano
corporate.communications@bauschhealth.com
(908) 569-3692

SOURCE: Bausch Health Companies Inc.



View the original press release on ACCESS Newswire

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  222.03
+0.00 (0.00%)
AAPL  262.77
+0.00 (0.00%)
AMD  238.03
+0.00 (0.00%)
BAC  51.52
+0.00 (0.00%)
GOOG  251.34
+0.00 (0.00%)
META  733.27
+0.00 (0.00%)
MSFT  517.66
+0.00 (0.00%)
NVDA  181.16
+0.00 (0.00%)
ORCL  275.15
+0.00 (0.00%)
TSLA  442.60
+0.00 (0.00%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.